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Abstract
Ginsenosides, the bioactive components of ginseng, can be divided into two major groups, namely 20(S)-
protopanaxatriol (e.g. Re, Rg1,R g 2, and Rb3) and 20(S)-protopanaxadiol (e.g. Rb1,R b 2, Rc, and Rd). Biological and
environmental factors may affect the content of ginsenosides in different parts of ginseng plant. Evidence from
pharmacokinetic and metabolic studies of Re demonstrated that (1) the absorption of Re is fast in gastrointestinal
tract; (2) Re may be metabolized mainly to Rh1 and F1 by intestinal microflora before absorption into blood; and
(3) Re is quickly cleared from the body.
Background
Ginseng is a key herb in Chinese medicine, and has a
wide range of therapeutic and pharmacological uses
[1-3]. Panax ginseng is a slow growing perennial herb of
the Araliaceae family usually cultivated in China, Japan,
Korea and Russia, as well as in the United States and
Canada. Ginseng root has been used as an oriental folk
medicine for several thousand years [2,4]. It is a highly
valued medicinal plant in the Far East that and also
popular in the West in the past 20 years [2,4-7].
A number of studies suggest that both Panax ginseng
C.A. Meyer (also known as Asian ginseng, Chinese gin-
seng or Korea ginseng) and Panax quinquefolius (also
known as American ginseng) have multiple components
and pharmacological functions [7-14]. Among the com-
plex constituents of ginseng, ginsenosides (also known
as ginseng saponins or triterpene saponins) are the
major components responsible for biochemical and
pharmacological actions of ginseng [9,15-17]. With the
development of modern technology, more than 150
naturally occurring ginsenosides have been isolated from
Panax species [18]. About 40 ginsenosides have been
identified from the root of Panax ginseng [1,19-22].
In order to explore the pharmacological actions,
mechanisms and clinical applications of ginseng, some
researchers focused on purified individual ginsenosides
rather than whole ginseng extracts [1,23]. Individual gin-
senosides may have different characteristics in chemis-
try, metabolism, and pharmacokinetics. Ginsenoside Re
(Re) belongs to 20(S)-protopanaxatriol group (Figure 1),
and is a major ginsenoside in ginseng [7,10,16,22,24-27].
Literature shows that Re exhibits multiple pharmacolo-
gical activities via different mechanisms [12,16,28]. For
example, in cardiovascular system, Re possesses negative
effects on cardiac contractility and autorhythmicity,
anti-arrhythmic and anti-ischemic effects, angiogenic
regeneration activities and cardiac electrophysiological
functions [28]. Xie et al.a n dL iet al. [13,29-32] found
that the quantity of Re in ginseng leaf and berry is
much higher than in ginseng main root and suggested
that ginseng leaf-stem could be a valuable source for Re.
There have been other new findings in recent years.
This article provides an overview of the recent advances
in chemistry, metabolism and pharmacokinetics of Re.
Chemistry and content
Chemical structure of Re
Rg1, Rc, Rd, Re, Rb1,R b 2 and Rb0 are the main ginseno-
sides in quantity [1,33]. The top six major ginsenosides
(Rb1, Re, Rd, Rc, Rg1 and Rb3)m a k eu po v e r7 0 %o f
total ginsenoside content in P. quinquefolius [34,35].
Ginsenosides are the glycosides that contain aglycone
with dammarane (except Ro). Ginsenosides (Figure 2)
are generally divided into two groups, namely the proto-
panaxadiol (PPD) and protopanaxatriol (PPT) ginseno-
side groups. The sugar moities in the PPD group
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any medium, provided the original work is properly cited.including Rb1,R b 2, Rc, Rd, Rg3 and Rh3, attach to the 3-
position of dammarane-type triterpine, whereas the
sugar moities in the PPT group including Re, Rf, Rg1,
Rg2 and Rh1, attach to the 6-position of dammarane-
type triterpine. A ginsenoside possesses a rigid four
trans-ring steroid skeleton with a modified side chain at
C-20 [1,17,36-39]. The chemical structures of ginseno-
sides are different from each other in the number, link-
age position and type of sugar [17,39]. During
extraction, sugar moieties of ginsenosides may be
cleaved by acid hydrolysis or endogenous glycosidases to
give corresponding aglycones [25,36]. PPD and PPT may
rearrange into panaxadiol and panaxatriol, respectively,
to provide artificial ginsenoside products. Kang et al.
[40] showed that PPD and PPT ginsenoside groups had
different bioactivities, even opposite effects. Recently,
Zhu et al. [41] found six new PPT-type ginsenosides
extracted from the P. ginseng root, named Re1 to Re6
(compounds 1-6) respectively, along with ten other
known PPT ginsenosides.
Content of Re in ginseng
The biological and environmental factors that may affect
t h eq u a n t i t ya n dq u a l i t yo fg i n s e n o s i d e si ng i n s e n g
[14,35] include the species, age, part of the plant, season
of harvest, method of cultivation, and means of preser-
vation. For example, the content of Re, Rg1 and Rd is
higher in the wild P. ginseng roots than in the cultivated
ginseng roots, while the content of Rc, Rb2 and Rb1 is
lower in the wild P. ginseng r o o t st h a ni nt h ec u l t i v a t e d
ones. These differences in content of ginsenosides might
affect their biological and pharmacological properties.
Root ginsenoside content depends on the age of ginseng
plant. For example, the plants younger than four years
of age are considered unsuitable for harvest due to their
low ginsenoside content [35,42-44]. Lim et al.[ 3 5 ]
determined the genotypes and environmental factors
affecting the ginsenoside content among eight wild
populations of P. quinquefolius.T h ei n f l u e n c eo fg e n o -
types and environment on ginsenoside content varies
among different types of ginsenosides. Specifically, the
Re content varies with populations but not locations,
whereas Rb1,R ca n dR b 2 only varies with locations, and
Rg1 and Rd varies with both. Ginsenoside levels are
decreased, while ginseng growth is increased, at an
intensively managed garden location. The content and
composition of ginsenosides vary with other environ-
mental conditions such as the type of soil, temperature,
light intensity and water content [45].
Using high pressure microwave-assisted extraction
(HPMAE) and high-performance liquid chromatography
(HPLC) coupled with evaporative light scattering detec-
tion (ELSD), i.e. HPMAE HPLC-ELSD, Qu et al. [46]
studied the effects of different parts and age of P. quin-
quefolius on the content of 12 ginsenosides, namely Rg1,
Re, Rf, Rg2,R h 1,R b 1, Rc, Rb2,R b 3, Rd, Rh2 and F11. The
study ranked the parts of five-years-old P. quinquefolius
in terms of total content of these 12 ginsenosides in a
descending order: leaf, root-hair, rhizome, main root
and stem, suggesting that the leaf could be a better
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Figure 1 Chemical structure of ginsenoside Re (MW = 946).
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Figure 2 Chemical structures of protopanaxadiol (A) and
protopanaxatriol (B).
Peng et al. Chinese Medicine 2012, 7:2
http://www.cmjournal.org/content/7/1/2
Page 2 of 6source for ginsenosides, as compared with other parts of
ginseng plant. It also found that in ginseng roots, the
content of Re and Rb1, the major ginsenosides, increase
with age of the plant.
In a comparative study on the quality of Tongrentang
Red Ginseng and Korean Red Ginseng, Wu et al [47]
found that the content of Re, Rg1 and Rb1 in the Ton-
grentang Red Ginseng is less than the content in the
Korean Red Ginseng.
Another extensive study [48] performed a quantitative
analysis of Re, Rb1 and Rg1 in P. quinquefolius berry
and flower sampled in various months throughout the
year, by enzyme-linked immunosorbent assay (ELISA).
The P. quinquefolius flower had higher content of Re,
Rb1 and Rg1 and the lowest content of Re in the berries
harvested in September [48]. To analyze the Re content
in P. quinquefolius berry pulp extracts, Morinaga et al.
[49] performed a new Eastern blot technique with anti-
Re monoclonal antibody, and confirmed that the con-
tent of Re varies from part to part in the plant.
Lee et al. [50] reported the variations in the ginseno-
side profiles of ginseng landraces in Korea. They found
that the P. ginseng wild population exhibits three types
of ginsenoside profiles affected by genetic and environ-
mental factors.
Metabolism and pharmacokinetics
Re has recently been studied extensively [12,13,30]; how-
ever, little is known about the metabolic and pharmaco-
kinetic profiles.
Absorption
After oral administration, Re is in contact with the gas-
triointestinal fluids containing gastric acids and gastric
enzymes, intestinal enzymes, and colonic bacteria [51,52].
Li et al. [23,53] studied the pharmacokinetic parameters
and absolute bioavailability of Re, R1,R g 1,R d ,a n dR b 1
after oral or intravenous administration of total notoginse-
nosides. Main pharmacokinetic parameters of these con-
stituents were determined by Drug and Statistics (DAS)
for Windows pharmacokinetics software. The results
showed that Re, R1,R g 1, Rd and Rb1 reached peak concen-
tration in plasma within about 45 minutes after oral
administration of total panax notoginsenoside (TPNG)
powder in rats, suggesting a rapid absorption of ginseno-
sides in gastrointestinal tract. The absolute bioavailability
of Re was 7.06% [53]. To confirm the rapid absorption
finding, Joo et al. [27] conducted a pharmacokinetic study
using ICR mice and ultra performance liquid chromato-
graphy-electrospray ionization-mass spectrometry (UPLC-
ESI-MS) analytical method. This pharmacokinetic study
[27] revealed that the time to reach the peak plasma con-
centration after oral administration was 0.4 ± 0.2 hour.
The data also showed that the oral bioavailability was
0.19-0.28%. Qi et al. [54] found that the oral bioavailability
of PPD ginsenosides (Ra3,R b 1, Rd, Rg3 and Rh2) and PPT
ginsenosides (Rg1, Re, Rh1,a n dR 1) was less than 5% and
PPT ginsenosides had better bioavailability, possibly due
to the faster degradation of PPD ginsenosides.
Metabolism and biotransformation
Han et al.[ 5 5 ]s h o w e dt h a tP P Tg i n s e n o s i d e sa r eh y d r o l y z -
able to Rh1 under mild acidic conditions. Tabaw et al. [56]
found that two degradation products of the PPT ginseno-
sides, Rh1 and F1 could reach the systemic circulation in
humans in addition to compound-K resulting from the
stepwise deglycosylation of PPD ginsenosides. Bae et al.
[57] further confirmed that the PPT (Re and Rg1) could be
metabolized mainly to Rh1 and G-F1 in the gastrointestinal
tract by intestinal microflora, before absorption into the
blood. Chi and Ji et al. [58] tested the biotransformation of
Re and Rb1 by cell extracts from various food-grade edible
microorganisms. As shown in Figure 3, Re was transformed
into Rh1 via Rg2 by Bif. sp. Int57 and Bif. sp.S J 3 2 ;A. niger
transformed Re into Rh1 via Rg1; A. usamii transformed Re
into Rg2. However, Rb1 was transformed into compound-K
and Rh1 by different pathways [58].
Metabolic research of Re in animals was also reported
[59]. Six SD rats were used and divided into three
groups. Feces were collected at 12, 24, 36, 48 and 60
hours after oral administration of Re (100mg/kg). Six
metabolites of Re were detected in the feces of rat. The
structures of the metabolites were identified as 20(S)-
ginsenoside Rg2, 20(S)-ginsenoside Rh1,2 0 ( R ) - g i n s e n o -
side Rh1,g i n s e n o s i d eF 1, 3-oxo-ginsenoside Rh1 and
PPT. The metabolic pathways of Re in animals were
similar to those in humans [59].
A similar metabolic study was also carried out in vivo
with HPLC coupled with electrospray ionization and
quadrupole time-of-flight tandem mass spectrometry
(HPLC-ESI-TOF-MS/MS) [60]. The rat urine samples
were collected and pretreated through C(18) solid-phase
extraction cartridges prior to analysis. As a result, eleven
and nine metabolites together with Re were detected
and identified in rat urine after oral and intravenous
administration, respectively. Oxidation and deglycosyla-
tion were found to be the major metabolic processes of
the constituent in rat, indicating that a large part of the
intact ginsenosides was metabolized and transformed to
ginsenosides with more biological effects in the gastroin-
testinal tract [52]. PPT ginsenosides, such as Re and Rg1,
were mainly converted to Rh1 and F1 and then to corre-
sponding aglycones [51,56].
Elimination
Xia et al. [38] applied a developed and validated liquid
chromatography-electrospray ionization-mass spectrome-
try (LC-ESI-MS) method to detect Re, Rg1,R d ,R b 1 and
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nated quickly from the body. The pharmacokinetic beha-
viors of Rd and Rb1 were significantly different from those
of Re and Rg1 in rat. Joo et al.[ 2 7 ]f o u n dt h a tR ew a s
rapidly cleared from the body within 0.2 ± 0.03 hour for
male mice and 0.5 ± 0.08 hour for female mice after intra-
venous administration. They also found that ginseng berry
extract exhibited a superior oral absorption of Re as com-
pared to orally fed Re, suggesting that ginseng berry
extract may be of choice for Re intake [27].
The plasma concentrations of Re and Rg1 were deter-
mined and the pharmacokinetic parameters were calcu-
lated after intravenous Shenmai injection in ten
volunteers [61]. The study found the distribution and
elimination of Re and Rg1 to be rapid after intravenous
injection; and the pharmacokinetic characteristics could
be fitted to the two-compartment model of
pharmacokinetics.
Conclusion
Multiple biological and environmental factors affect the
quantity and quality of ginsenosides in ginseng parts.
Studies on Re demonstrate that (1) the absorption of Re
is quick in rats; (2) PPT, Re and Rg1, are likely to be
metabolized to Rh1 and F1 by intestinal microflora
before absorption into the blood; and (3) Re can be
quickly eliminated from the body.
Abbreviations
DAS: Drug and Statistics for Windows pharmacokinetic software; ELISA:
enzyme-linked immunosorbent assay; Re: ginsenoside Re (Rg1,R g 2,R g 3, Rf,
Rb1,R b 2,R b 3, Rc, Rd, and Re1 -R e 6 are the same abbreviations with Re);
HPLC-ESI-TOF-MS/MS: high-performance liquid chromatography coupled
with electrospray ionization and quadrupole time-of-flight tandem mass
spectrometry; HPLC-ELSD: high-performance liquid chromatography coupled
with evaporative light scattering detection; HPMAE: high pressure
microwave-assisted extraction; PPD: protopanaxadiol; LC-ESI-MS: liquid
chromatography-electrospray ionization-mass spectrometry; PPT:
protopanaxatriol; TPNG: total Panax notoginsenoside; UPLC/MS: ultra
performance liquid chromatography mass spectrometry
Acknowledgements
The work of LHX is supported by NIH/NHLBI R01 HL97979.
Author details
1The Ben May Department for Cancer Research, Pritzker School of Medicine,
The University of Chicago, Chicago, IL 60637, USA.
2Section of Emergency
Medicine, Pritzker School of Medicine, The University of Chicago, Chicago, IL
60637, USA.
3College of Grain Oil and Food Science, Henan University of
Technology, 140 Songshan South Road, Zhengzhou 450052, China.
4Department of Cell Biol & Mol Med, UMDNJ-New Jersey Medical School,
185 South Orange Ave. MSB C609, Newark, NJ 07103, USA.
5Department of
Biological Sciences, City Colleges of Chicago, 1900 W. Van Buren Street,
Chicago, IL 50512, USA.
6University of Illinois at Chicago, 909 S. Wolcott Ave.
Chicago, IL 60612, USA.
7Shangqiu Medical College, 486 W. Beihei Street,
Shangqiu, Henan 476000, China.
Authors’ contributions
JTX and LHX conceived study. DCP, HSW, CLQ and SMW collected the data.
DCP, HSW, CLQ, LHX, SMW and JTX wrote the manuscript. The authors have
read and approved the final version of the manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 21 July 2011 Accepted: 7 February 2012
Published: 7 February 2012
OH
OH
OGlc - Rha
GlcO
HO
OH
OGlc
GlcO
- Glc
Rg1
HO
OH
OGlc
HO
Rh1
 Re
Figure 3 Proposed possible metabolism pathway of G-Re by
stomach acidity and large intestine bacteria.
Peng et al. Chinese Medicine 2012, 7:2
http://www.cmjournal.org/content/7/1/2
Page 4 of 6References
1. Lu JM, Yao Q, Chen C: Ginseng compounds: an update on their
molecular mechanisms and medical applications. Curr Vasc Pharmacol
2009, 7(3):293-302.
2. Peng DC, Chen WP, Xie JT: Antihyperglycemic effects of ginseng and
possible mechanisms. Drugs of the future 2008, 33(6):507-514.
3. Hofseth LJ, Wargovich MJ: Inflammation, cancer, and targets of ginseng. J
Nutr 2007, 137(1 Suppl):183S-185S.
4. Chevallier A: Encyclopedia of herbal medicine. New York: DK Publishing
Inc; 2000.
5. Blumenthal M, Goldberg A, Brinckmann J: Ginseng root. Newton, MA:
Integrative Medicine Communications; 2000.
6. Barnes PM, Powell-Griner E, McFann K, Nahin RL: Complementary and
alternative medicine use among adults: United States, 2002. Adv Data
2004, 343:1-19.
7. Helms S: Cancer prevention and therapeutics: Panax ginseng. Altern Med
Rev 2004, 9(3):259-274.
8. Hu SY: A contribution to our knowledge of ginseng. Am J Chin Med 1977,
5(1):1-23.
9. Attele AS, Wu JA, Yuan CS: Multiple pharmacological effects of ginseng.
Biochem Pharmacol 1999, 58:1685-1693.
10. Attele AS, Zhou YP, Xie JT, Wu JA, Zhang L, Dey L, Pugh W, Rue PA,
Polonsky KS, Yuan CS: Antidiabetic effects of Panax ginseng berry extract
and the identification of an effective component. Diabetes 2002,
51(6):1851-1858.
11. Lee TK, Johnke RM, Allison RR, O’Brien KF, Dobbs LJ Jr: Radioprotective
potential of ginseng. Mutagenesis 2005, 20(4):237-243.
12. Xie JT, Mehendale SR, Li X, Quigg R, Wang X, Wang CZ, Wu JA, Aung HH,
Rue PA, Bell GI, Yuan CS: Anti-diabetic effect of ginsenoside Re in ob/ob
mice. Biochim Biophys Acta 2005, 1740(3):319-325.
13. Wang H, Peng D, Xie J: Ginseng leaf-stem: bioactive constituents and
pharmacological functions. Chin Med 2009, doi:10.1186/1749-8546-4-20.
14. Peng L, Sun S, Xie L-H, Wicks SM, Xie J-T: Ginsenoside Re: Pharmacological
Effects on Cardiovascular System. Cardiovascular Therapeutics 2011.
15. Lee SJ, Sung JH, Moon CK, Lee BH: Antitumor activity of a novel ginseng
saponin metabolite in human pulmonary adenocarcinoma cells resistant
to cisplatin. Cancer Lett 1999, 144(1):39-43.
16. Xie JT, Shao ZH, Vanden Hoek TL, Chang WT, Li J, Mehendale S, Wang CZ,
Hsu CW, Becker LB, Yin JJ, et al: Antioxidant effects of ginsenoside Re in
cardiomyocytes. Eur J Pharmacol 2006, 532(3):201-207.
17. Qi LW, Wang CZ, Yuan CS: American ginseng: potential structure-function
relationship in cancer chemoprevention. Biochem Pharmacol 2010,
80(7):947-954.
18. Shi YSC, Zheng B, Li Y, Wang Y: Simultaneous determination of nine
ginsenosides in functional foods by high performance liquid
chromatography with diode array detector detection. Food Chemistry
2010, 123:1322-1327.
19. Gillis CN: Panax ginseng pharmacology: a nitric oxide link? Biochem
Pharmacol 1997, 54(1):1-8.
20. Fuzzati N: Analysis methods of ginsenosides. J Chromatogr B Analyt
Technol Biomed Life Sci 2004, 812(1-2):119-133.
21. Cheng Y, Shen LH, Zhang JT: Anti-amnestic and anti-aging effects of
ginsenoside Rg1 and Rb1 and its mechanism of action. Acta Pharmacol
Sin 2005, 26(2):143-149.
22. Xie JT, Wang CZ, Wang AB, Wu J, Basila D, Yuan CS: Antihyperglycemic
effects of total ginsenosides from leaves and stem of Panax ginseng.
Acta Pharmacol Sin 2005, 26(9):1104-1110.
23. Li X, Sun J, Wang G, Hao H, Liang Y, Zheng Y, Yan B, Sheng L:
Simultaneous determination of panax notoginsenoside R1, ginsenoside
Rg1, Rd, Re and Rb1 in rat plasma by HPLC/ESI/MS: platform for the
pharmacokinetic evaluation of total panax notoginsenoside, a typical
kind of multiple constituent traditional Chinese medicine. Biomed
Chromatogr 2007, 21(7):735-746.
24. Ota T, Fujikawa-Yamamoto K, Zong ZP, Yamazaki M, Odashima S,
Kitagawa I, Abe H, Arichi S: Plant-glycoside modulation of cell surface
related to control of differentiation in cultured B16 melanoma cells.
Cancer Res 1987, 47:3863-3867.
25. Banthorpe DV: Terpenoids. Natural Products. In. Essex: Longman Scientific
and Technical 1994, 331-339.
26. Kim YS, Kim DS, Kim SI: Ginsenoside Rh2 and Rh3 induce differentiation
of HL-60 cells into granulocytes: modulation of protein kinase C
isoforms during differentiation by ginsenoside Rh2. Intl J Biochem Cell Biol
1998, 30:327-338.
27. Joo KM, Lee JH, Jeon HY, Park CW, Hong DK, Jeong HJ, Lee SJ, Lee SY,
Lim KM: Pharmacokinetic study of ginsenoside Re with pure ginsenoside
Re and ginseng berry extracts in mouse using ultra performance liquid
chromatography/mass spectrometric method. J Pharm Biomed Anal 2010,
51(1):278-283.
28. Peng L, Sun S, Xie L-H, Wicks SM, Xie JT, Ginsenoside Re: Pharmacological
effects on cardiovascular system. Cardiovasc Therap 2011, doi:10.1111/
j.1755-5922.2011.00271.x.
29. Xie JT, Aung HH, Wu JA, Attele AS, Yuan CS: Effects of American ginseng
berry extract on blood glucose levels in ob/ob mice. Am J Chin Med
2002, 30(2-3):187-194.
30. Xie JT, Mehendale SR, Wang A, Aung HH, Wu J, Osinski J, Yuan C-S:
American ginseng leaf: Ginsenoside analysis and hypoglycemic activity.
Pharmacol Res 2004, 49:113-117.
31. Li TSC, Mazza G, Cottrell AC, Gao L: Ginsenosides in roots and leaves of
American ginseng. J Agric Food Chem 1996, 44:717-720.
32. Xie JT, Mehendale SR, Wang A, Han AH, Wu JA, Osinski J, Yuan CS:
American ginseng leaf: ginsenoside analysis and hypoglycemic activity.
Pharmacol Res 2004, 49(2):113-117.
33. Dharmananda S: The nature of ginseng: traditional use, modern research,
and the question of dosage. Herbalgram 2002, 54:34-51.
34. Wang A, Wang CZ, Wu JA, Osinski J, Yuan CS: Determination of major
ginsenosides in Panax quinquefolius (American ginseng) using high-
performance liquid chromatography. Phytochem Anal 2005, 16(4):272-277.
35. Lim W, Mudge KW, Vermeylen F: Effects of population, age, and
cultivation methods on ginsenoside content of wild American ginseng
(Panax quinquefolium). J Agric Food Chem 2005, 53(22):8498-8505.
36. Shibata S, Tanaka O, Shoji J, Saito H: Chemistry and pharmacology of
Panax. Economic and Medicinal plant Research 1985, 1:217-283.
37. Luchtefeld R, Kostoryz E, Smith RE: Determination of ginsenosides Rb1, Rc,
and Re in different dosage forms of ginseng by negative ion
electrospray liquid chromatography-mass spectrometry. J Agric Food
Chem 2004, 52(16):4953-4956.
38. Xia C, Wang G, Sun J, Hao H, Xiong Y, Gu S, Shang L, Zheng C:
Simultaneous determination of ginsenoside Rg1, Re, Rd, Rb1 and
ophiopogonin D in rat plasma by liquid chromatography/electrospray
ionization mass spectrometric method and its application to
pharmacokinetic study of ‘SHENMAI’ injection. J Chromatogr B Analyt
Technol Biomed Life Sci 2008, 862(1-2):72-78.
39. Xie J-T, Attele AS, Yuan C-S: Ginseng: beneficial and potential adverse
effect. In A textbook of complementary and alternative therapies. Edited by:
Yuan C-S, Beiber E, Bauer BA. Boca Raton, London, New York, Washington,
D.C.: CRC Press Company; 2006:71-89.
40. Kang SY, Schini-Kerth VB, Kim ND: Ginsenosides of the protopanaxatriol
group cause endothelium-dependent relaxation in the rat aorta. Life
Sciences 1995, 56(19):1577-1586.
41. Zhu GY, Li YW, Hau DK, Jiang ZH, Yu ZL, Fong WF: Protopanaxatriol-type
ginsenosides from the root of Panax ginseng. J Agric Food Chem 2011,
59(1):200-205.
42. Mizuno M, Yamada J, Terai H, Kozukue N, Lee YS, Tsuchida H: Differences
in immunomodulating effects between wild and cultured Panax
ginseng. Biochem Biophys Res Commun 1994, 200(3):1672-1678.
43. Leung KW, Wong AS: Pharmacology of ginsenosides: a literature review.
Chin Med 2010, 5:20.
44. Schlag EM, Mclntosh MS: Ginsenoside content and variation among and
within American ginseng (Panax quinquefolius L.) populations.
Phytochemistry 2006, 67:1510-1519.
45. Mihalov JJ, Marderosian AD, Pierce JC: DNA identification of commercial
ginseng samples. J Agric Food Chem 2000, 48(8):3744-3752.
46. Qu C, Bai Y, Jin X, Wang Y, Zhang K, You J, Zhang H: Study on
ginsenosides in different parts and ages of Panax quinquefolius L. Food
Chemistry 2009, 115:340-346.
47. Wu JM, Lin HY, Zhao LH, Jia HT, Jia HK, Wang Y, Chen DW: Comparative
study on quality of Tongrentang red ginseng and Korean red ginseng-
determination of ginsenosides and polysaccharides. Zhongguo Zhong
Yao Za Zhi 2007, 32(7):573-577.
48. Sritularak B, Morinaga O, Yuan CS, Shoyama Y, Tanaka H: Quantitative
analysis of ginsenosides Rb1, Rg1, and Re in American ginseng berry
Peng et al. Chinese Medicine 2012, 7:2
http://www.cmjournal.org/content/7/1/2
Page 5 of 6and flower samples by ELISA using monoclonal antibodies. Nat Med
(Tokyo) 2009, 63(3):360-363.
49. Morinaga O, Uto T, Yuan CS, Tanaka H, Shoyama Y: Evaluation of a new
eastern blotting technique for the analysis of ginsenoside Re in
American ginseng berry pulp extracts. Fitoterapia 2009, doi:10.1016/j.
fitote.2009.10.005.
50. Lee M-J, Choi J-S, Cha S-W, Lee K-S, Lee Z-W, Hwang G-S, Lee SH,
Kamal AHM, Jung Y-A, Seung N-S, Woo S-H: Variation in the ginsenoside
profiles of cultivated ginseng (Panax ginseng C.A. Meyer) landraces in
Korea. Process Biochemistry 2011, 46(1):258-264.
51. Hasegawa H: Proof of the mysterious efficacy of ginseng: basic and
clinical trials: metabolic activation of ginsenoside: deglycosylation by
intestinal bacteria and esterification with fatty acid. J Pharmacol Sci 2004,
95(2):153-157.
52. Christensen L: Ginsenosides: Chemistry, Biosynthesis, Analysis, and
Potential Health Effects. Advances in Food and Nutrition Research 2008,
55:1-99.
53. Li X, Wang G, Sun J, Hao H, Xiong Y, Yan B, Zheng Y, Sheng L:
Pharmacokinetic and absolute bioavailability study of total panax
notoginsenoside, a typical multiple constituent traditional chinese
medicine (TCM) in rats. Biol Pharm Bull 2007, 30(5):847-851.
54. Qi L-W, Wang C-Z, Yuan C-S: Isolation and analysis if ginseng: advances
and challenges. Nat Prod Rep 2011, DOI: 10.1039/c0np000057d.
55. Han BH, Park MH, Han YN, Woo LK, Sankawa U, Yahara S, Tanaka O:
Degradation of Ginseng Saponins under Mild Acidic Conditions. Planta
Med 1982, 44(3):146-149.
56. Tawab MA, Bahr U, Karas M, Wurglics M, Schubert-Zsilavecz M: Degradation
of ginsenosides in humans after oral administration. Drug Metab Despos
2003, 31:1065-1071.
57. Bae EA, Shin JE, Kim DH: Metabolism of ginsenoside Re by human
intestinal microflora and its estrogenic effect. Biol Pharm Bull 2005,
28(10):1903-1908.
58. Chi H, Ji GE: Transformation of Ginsenosides Rb1 and Re from Panax
ginseng by Food Microorganisms. Biotechnol Lett 2005, 27(11):765-771.
59. Chen G, Yang M, Guo D: Metabolic study of ginsenoside Re in rats.
Zhongguo Zhong Yao Za Zhi 2009, 34(12):1540-1543.
60. Yang L, Xu S, Liu C, Su Z: In vivo metabolism study of ginsenoside Re in
rat using high-performance liquid chromatography coupled with
tandem mass spectrometry. Anal Bioanal Chem 2009, 395:1441-1453.
61. Liu YM, Yang L, Zeng X, Deng YH, Feng Y, Liang WX: Pharmacokinetics of
ginsenosides Rg1 and Re in Shenmai injection. Yao Xue Xue Bao 2005,
40(4):365-368.
doi:10.1186/1749-8546-7-2
Cite this article as: Peng et al.: Ginsenoside Re: Its chemistry,
metabolism and pharmacokinetics. Chinese Medicine 2012 7:2.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Peng et al. Chinese Medicine 2012, 7:2
http://www.cmjournal.org/content/7/1/2
Page 6 of 6